1990 Volume 38 Issue 5 Pages 489-498
We used cefixime (CFIX) in the treatment of 65 patients with respiratory infections: 50 with acute respiratory infection, including 27 with bronchitis and 23 with pneumonia. The other 15 patients were considered to have chronic respiratory infections, including chronic bronchitis, bronchiectasis 4, bronchiolitis 1, and 6 cases of other lung diseases with secondary infection. CFIX in 100 mg capsules was administered orally. As a rule, the daily dose was 200 mg.
The efficacy rate was 80.0% in the 50 patients with acute infections, and 60.0% in the 15 patients with chronic infections. CFIX showed satisfactory antibiotic activity in mild to moderate acute respiratory infections, for which 200 mg /day was an effective dose. On the other hand, the efficacy rate for the 200 mg /day dose was lower in chronic respiratory infections. Some additional therapy and/or 400 mg/day of CFIX should be given to patients with complicated respiratory infections. Side effects were observed in 6.1% of these patients, but none were serious. We consider CFIX to be a useful antibiotic in the treatment of respiratory infections.
